Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | IL-12/23 antibody for psoriasis and inflammatory bowel disease. | Biologic injection for arthritis, IBD and psoriasis. |
| Body system | Joints & Immunity | Joints & Immunity |
| Drug class | Interleukin inhibitors | TNF inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription only |
| Main uses | Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis | Rheumatoid and psoriatic arthritis, Ankylosing spondylitis, Crohn's disease and ulcerative colitis, Psoriasis, Hidradenitis suppurativa |
| How it works | Blocks inflammation signals IL-12 and IL-23. | Mops up a key inflammation signal. |
| Starts working | Weeks | — |
| Half-life | About 3 weeks | About 2 weeks |
| Typical adult dose | 45–90 mg subcutaneously at weeks 0 and 4 then every 12 weeks (psoriasis); IV induction in IBD. | 40 mg under the skin every other week (some conditions start higher or go weekly). |
| Forms | Subcutaneous injection, IV infusion (induction) | Pre-filled pen, Pre-filled syringe |
| Common side effects | Upper respiratory infections, Headache, Tiredness, Injection site redness | Injection-site reactions, Upper respiratory infections, Headache |
| Serious side effects | Serious infections, Allergic reactions, Reversible leukoencephalopathy (rare) | Serious infections including TB reactivation, Lymphoma (rare), Demyelination, Heart failure worsening |
| Don't take if | Active serious infection; Active TB | — |
| Alcohol | Usually no problem in moderation. No specific interaction. | — |
| Pregnancy | Use with cautionLimited data; may be continued when benefit outweighs risk. | Use with cautionOften continued into pregnancy for IBD; baby's live vaccines may be delayed. |
| Breastfeeding | Use with cautionLimited data. | — |
| In use since | — | 2002 |
| Brand names | United States: Stelara, WezlanaUnited Kingdom: Stelara, WezenlaIndia: Stelara, Ustekinumab biosimilars | United States: Humira, Hadlima, Hyrimoz, YuflymaUnited Kingdom: Humira, Amgevita, Imraldi, YuflymaIndia: Exemptia, Adfrar |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H | — |
| ATC code | L04AC05 | L04AB04 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker